# Cue Biopharma, Inc. (CUE) — capital_raise/private_placement [announced]
Source: sec.gov · situation sit_79014ae2e541b2ff0d29 · public 2055983803460968354 · retrieved 2026-08-20T13:14:58.110Z

## Overview
Cue Biopharma is a clinical-stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies for immune-mediated diseases, with lead asset CUE-221 (anti-IgE antibody in Phase 2 for allergic diseases) and CUE-401 (autoimmune candidate advancing toward Phase 1).

Cue Biopharma, Inc. completed a $50 million private placement (PIPE) financing to support clinical development and portfolio advancement. The company is a clinical-stage biopharmaceutical company focused on advancing transformative therapies for immune-mediated diseases, with lead asset CUE-221 in Phase 2 development for allergic diseases and CUE-401 advancing toward Phase 1 clinical trials.

## Terms
- Deal value: $50.0M · Consideration: cash

## Key dates
- Announced 2026-08-14

## Timeline
- 2026-08-14 · 8-K (0001193125-26-352126): 8-K - Cue Biopharma, Inc. — *Cue Biopharma is a clinical-stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies for immune-mediated diseases, with lead asset CUE-221 (anti-IgE antibody in Phase 2 for allergic diseases) and CUE-401 (autoimmune candidate advancing toward Phase 1).* Cue Biopharma, Inc. completed a $50 million private placement (PIPE) financing to support clinical development and portfolio advancement. The company is a clinical-stage biopharmaceutical company focused on advancing transformative therapies for immune-mediated diseases, with lead asset CUE-221 in Phase 2 development for allergic diseases and CUE-401 advancing toward Phase 1 clinical trials.
  https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-352126.txt

## Citations
- 0001193125-26-352126 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526352126